What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2025-05-09 compared with 2025-01-24 · 88 added, 80 removed, 67 unchanged (71% of the section changed)

5 unchanged sentences

The financial data discussed below are derived

from the unaudited consolidated financial statements of the Company as of November 30, 2024, which were prepared and presented in accordance

from the unaudited consolidated financial statements of the Company as of February 28.

2025, which were prepared and presented in accordance

with United States generally accepted accounting principles for interim financial statements.

3 unchanged sentences

in its Annual Report on Form 10-K for the year ended May 31, 2024, filed with the SEC on August 16, 2024.

Further, the Company urges

caution regarding the forward-looking statements which are contained in this report because they involve risks, uncertainties and other

factors affecting its operations, market growth, service, products and licenses that may cause the Company’s actual results and

achievements, whether expressed or implied, to differ materially from the expectations the Company describes in its forward-looking statements.

Further, the Company urges caution

regarding the forward-looking statements which are contained in this report because they involve risks, uncertainties and other factors

affecting its operations, market growth, service, products and licenses that may cause the Company’s actual results and achievements,

whether expressed or implied, to differ materially from the expectations the Company describes in its forward-looking statements.

General Statement of Business

6 unchanged sentences

firm, there is substantial doubt as to the ability of the Company to continue as a going concern.

The Company has incurred recurring

losses and recurring negative cash flow from operating activities and has an accumulated deficit, and its ability to continue as a going

concern depends on the successful execution of its operating plan, increasing sales of existing services and introducing new products

and services, as well as raising either debt or equity financing.

The Company has incurred recurring losses

and recurring negative cash flow from operating activities and has an accumulated deficiency, and its ability to continue as a going concern

depends on the successful execution of its operating plan, which includes the increasing sales of existing services and introducing new

services, as well as raising either debt or equity financing.

The Company needs substantial additional capital

5 unchanged sentences

Results of Operations

Comparison of the Three Months Ended November 30, 2023, and

November 30, 2022

Comparison of the Three Months Ended February 28, 2025, and

February 29, 2024

The following table sets forth information from

the statements of operations for the three months ended November 30, 2023, and November 30, 2022.

Three Months Ended November 30,

the statements of operations for the three months ended February 28, 2025, and February 29, 2024.

Three Months Ended

February 28, 2025

February 29, 2024

Cost of revenues

Total operating expenses

Gross profit (loss)

Total operating expense

Operating loss

Amortization of note discount

Non-operating expense:

Note discount

Change in value of derivative liabilities

Revenues were $14,931 and $36,411 for the three

months ended November 30, 2024, and November 30, 2023, respectively.

The increase was primarily due to a $10,500 increase in revenues

from clinical trials sales.

months ended February 28, 2025, and February 29, 2024, respectively.

The decrease was primarily due to a $14,680 decrease in revenues

from clinical trials.

Cost of Revenues

Cost of revenues for the three months ended November

30, 2024, and November 30, 2023, were $7,803 and $15,092, respectively.

The difference was primarily due to a reduction in cost of revenues

in clinical trials.

Total Operating Expenses

Cost of revenues for the three months ended February

28, 2025, and February 29, 2024, were $19,396 and $11,809, respectively.

The difference was primarily due to an increase of $7,587 in

cost of revenues in clinical trials.

Total Operating Expense

The following table sets forth total operating

expenses for the three months ended November 30, 2024, and November 30, 2023:

Three Months Ended November 30,

expenses for the three months ended February 28, 2025, and February 29, 2024:

Three Months Ended

February 28, 2025

February 29, 2024

General and administrative

2 unchanged sentences

Officer compensation

Rent and lease

Total operating expenses

Total operating expenses were $124,769 and $184,573

for the three months ended November 30, 2024, and November 30, 2023, respectively.

for the three months ended February 28, 2025, and February 29, 2024, respectively.

The decrease is attributable to reductions of $85,344

$6,000 and $12,771 in professional fees, officer compensation and rent and lease, respectively, offset by an increase of $31,721 in general

and administrative.

in professional fees, offset by increases of $24,883 and $7,038 in general and administrative and contract labor, respectively.

Operating Loss

Operating income/loss increased from a loss of

$94,512 for the quarter ended November 30, 2023 to a loss of $59,627 for the three months ended November 30, 2024, primarily due to an

increase of revenue from clinical trial of $10,500 and a decrease in total operating expenses of $17,096.

For the three months ended November 30, 2024,

and November 30, 2023, interest was $8,701 and $29,916, respectively, while the note discount expense was $11,200 for the three months

ended November 30, 2024.

Net income for the three months ended November

30, 2024 was $79,528 versus the net loss of $124,428 for the three months ended November 30, 2023, for the reasons described above.

Comparison of the Six Months Ended November 30, 2024, and November

Operating loss decreased from $159,971 for the

quarter ended February 29, 2024, to $129,234 for the three months ended February 28, 2025, due to the decrease in total operating expenses

described above.

Other Expense

For the three months ended February 28, 2025,

the Company recorded amortization of note discount of $13,138 for the three months ended February 28, 2025, compared with $0 for the three

months ended February 29, 2024, interest of $22,473 for the three months ended February 28, 2025, compared with $49,221 for the three

months ended February 29, 2024, and change in value of derivative liabilities of $16,398 for the three months ended February 28, 2025,

compared with $0 for the three months ended February 29, 2024.

Net loss for the three months ended February 28,

2025, was $181,243 versus $209,192 for the three months ended February 29, 2024, for the reasons described above.

Comparison of the Nine Months Ended February 28, 2025, and

February 29, 2024

The following table sets forth information from

the statements of operations for the six months ended November 30, 2024, and November 30, 2023.

Six Months Ended November 30,

the statements of operations for the nine months ended February 28, 2025, and February 29, 2024.

Nine Months Ended

February 28, 2025

February 29, 2024

Cost of revenues

Total operating expenses

Total operating expense

Operating loss

Non-operating income (expense):

Amortization of note discount

Forgiveness of debt

Note discount

Revenues were $253,135 and $136,569 for the six

months ended November 30, 2024, and November 30, 2023, respectively.

The increase was primarily due to increase in clinical trial and

consulting fees amounting to $137,199 and $16,667, respectively.

Change in value of derivative liabilities

Revenues were $268,066 and $172,979 for the nine

months ended February 28, 2025, and February 29, 2024, respectively.

The increase was primarily due to an increase of $95,087 in revenue

from clinical trials.

Cost of Revenues

Cost of revenues for the six months ended November 30, 2024, and November

30, 2023, were $16,165 and $23,912, respectively.

The difference was primarily due to a $7,747 decrease in cost of revenues for clinical

Total Operating Expenses

Cost of revenues for the nine months ended February

28, 2025, and February 29, 2024, were $35,561 and $35,721, respectively.

Total Operating Expense

The following table sets forth total operating

expenses for the six months ended November 30, 2023, and November 30, 2022:

Six Months Ended November 30,

expenses for the nine months ended February 29, 2024, and November 30, 2022:

Nine Months Ended November 30,

General and administrative

4 unchanged sentences

Total operating expenses were $518,970 and $593,764

for the six months ended November 30, 2024, and November 30, 2023, respectively.

for the nine months ended February 28, 2025, and February 29, 2024, respectively.

The decrease was primarily attributable to reductions

of $41,811, $15,476 and $12,000 in contract labor, rent and lease, and officer compensation, respectively, offset by an increase of $48,048

in general and administrative..

of $28,174 and $43,084 in contract labor and professional, respectively, offset by an increase of $37,584 in general and administrative.

Operating Loss

Operating loss decreased from $456,506 for the

six months ended November 30, 2023, to $157,231 for the six months ended November 30, 2024, primarily due to increase in revenue from

clinical trial amounting to $137,199 and decrease in operating expense from contract labor of $41,811.

nine months ended February 29, 2024, to $286,465 for the nine months ended February 28, 2025, primarily due to an increase of $158,746

in revenue from clinical trials and a decrease in operating expense from professional fees of $49,084.

Other Income (Expense)

For the six months ended November 30, 2024, and

November 30, 2023, interest was $11,040 and $38,035, respectively.

During the six months ended November 30, 2024, the Company recorded

income of $23,638 from forgiveness of a loan and an expense from note discount amounting to $11,200.

As a result, other income (expense)

for the six months ended November 30, 2024, and November 30, 2023, showed income of $1,398 and loss of $38,035, respectively.

The net loss for the six months ended November

30, 2024, was $155,833, versus $306,217 for the six months ended November 30, 2023, for the reasons described above.

For the nine months ended February 28, 2025, and

February 29, 2024, interest was $33,513 and $58,904, respectively.

During the nine months ended February 28, 2025, the Company recorded

income of $23,638 from the forgiveness of a loan and an expense from amortization of note discount of $$24,338.

Additionally, the Company

incurred a change in value of derivative liabilities of $16,398.

As a result, other income (expense) for the nine months ended February

28, 2025, and February 29, 2024, were losses of $50,611 and $58,904, respectively.

Net loss for the nine months ended February 28,

2025, was $337,076 versus $515,410 for the nine months ended February 29, 2024, for the reasons described above.

Changes in Financial Condition and Results

of Operations

At November 30, 2024, the Company had $1,002

in cash and cash equivalents and accounts receivable of $13,819, negative working capital of $857,255 and no commitments for capital

expenditures.

At May 31, 2024, the Company had $755 in cash and cash equivalents and accounts receivable of $20,139, negative working

capital of $860,416 and no commitments for capital expenditures.

The Company had a balance of cash and cash equivalents of $1,002 on

the date of this Report.

During the six months ended November 30, 2024,

the Company had net cash used in operations of $102,503, while during the quarter ended November 30, 2023, the Company had net cash used

in operations of $295,867.

On the other hand, during the six months ended November 30, 2024, the Company had net cash provided in financing

of $102,750, while during the quarter ended November 30, 2023, the Company had net cash provided in financing of $287,290.

years ended May 31, 2024, and May 31, 2023, the Company had net cash used in operations of $479,382 and $898,367, respectively, and net

cash provided by financing activities of $471,224 and $875,298, respectively.

The Company had accumulated deficits of $5,273,234 at November

30, 2024, and $5,334,081 at May 31, 2024.

At February 28, 2025, the Company had $548 in

cash and cash equivalents and accounts receivable of $2,640, negative working capital of $966,272 and no commitments for capital expenditures.

At May 31, 2024, the Company had $755 in cash and cash equivalents and accounts receivable of $20,139, negative working capital of $860,416

and no commitments for capital expenditures.

The Company had cash and cash equivalents of $177 on the date of this Report.

During the nine months ended February 28, 2025,

the Company had net cash used in operations of $185,315, while during the nine months ended February 29, 2024, the Company had net cash

used in operations of $304,943.

During the nine months ended February 28, 2025, the Company had net cash provided by financing activities

of $185,108, while during the nine months ended February 29, 2024, the Company had net cash provided by financing activities of $296,824.

Off-Balance-Sheet Arran g ements

6 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q/A

Item 2. Management’s Discussion and Analysis